Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia

NCT01126502 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

30

Enrollment

NIH

Sponsor class

Stopped Administratively Complete.

Conditions

B-cell Chronic Lymphocytic Leukemia
Prolymphocytic Leukemia
Recurrent Small Lymphocytic Lymphoma
Refractory Chronic Lymphocytic Leukemia

Interventions

DRUG: alvespimycin hydrochloride
OTHER: diagnostic laboratory biomarker analysis
OTHER: pharmacogenomic studies
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)